The immunotherapeutic potential of melatonin

Bibliography

• SPECTOR NH, DOLINA S, CORNELISSEN G et al.:Neuroimmunomodulation: neuroimmune interac-tions with the environment. In: Handbook of Physiology: The Environment. Blatteis CM (Ed.), American Physiological Society, Bethesda, USA (1996):1437–1549.
   Google Scholar
• ADER R, COHEN N, FELTEN D: Psychoneuroimmu-nology: interactions between the nervous system and the immune system. Lancet (1995) 345 (8942):99–103.
   PubMed Web of Science ®Google Scholar
• YU H-S, TSIN ATC, REITER RJ: Melatonin: history,biosynthesis and assay methodology. In: Melatonin. Biosynthesis, Physiological Effects and Clinical Applications. Yu H-S, Reiter RJ (Eds.) CRC Press, Boca Raton, (1993):1–17.
   Google Scholar
• LERNER AB, CASE JD, TAKAHASHI Y et al.: Isolation ofmelatonin, the pineal gland factor that lightens melanocytes. J. Am. Chem. Soc. (1958) 80:2587–2592.
   Web of Science ®Google Scholar
• FEYCHTING M, OSTERLUND B, AHLBOM A: Reducedcancer incidence among the blind. Epidemiology (1998) 9:490–494.
   PubMed Web of Science ®Google Scholar
• •Epidemiological evidence of the possible anti-cancer action of endogenous MLT.
   Google Scholar
• REPPERT SM, WEAVER DR: Melatonin madness. Cell(1995) 83:1059–1062.
   PubMed Web of Science ®Google Scholar
• VANECEK J: Cellular mechanisms of melatonin action.Physiol. Rev. (1998) 78:687–721.
   PubMed Web of Science ®Google Scholar
• •Review of MEL receptors and signal transduction mechanisms.
   Google Scholar
• POON AM, LIU ZM, PANG CS et al.: Evidence for a directaction of melatonin on the immune system. Biol. Signals (1994) 3:107–117.
   PubMedGoogle Scholar
• MAESTRONI GJM: T helper 2 lymphocytes as a periph-eral target of melatonin. J. Pineal Res. (1995) 18:84–89.
   PubMed Web of Science ®Google Scholar
• MAESTRONI GJM, CONTI A: The pineal neurohormone melatonin stimulates activated CD4+, Thy-1+ cells to release opioid agonist(s) with immunoenhancing and anti-stress properties. J. Neuraimmunoi. (1990) 20:167–176.
   Google Scholar
• •Demonstration that the surprising ability of MEL to neutralise the immunological depression secondary to stress events or corticosteroid treatment is due to stimulation of T-helper cell-derived novel opioid cytokines.
   Google Scholar
• KONAKCHIEVA R, KYURKCHIEV S, KEHAYOV I et al.:Selective effect of methoxyndoles on the lymphocyte proliferation and melatonin binding to activated human lymphoid cells. J. NeuroimmunoL (1995) 63:125–132.
   PubMed Web of Science ®Google Scholar
• GARCIA-MAURINO S, GONZALES-HABA MG, CALVO JR etal.: Melatonin enhances IL-2, IL-6 and IFN-yproduction by human circulating CD4+ cells. J. Immunol. (1997) 159:574–581.
   Google Scholar
• •Confirmation of the immunoenhancing action of MEL in human lymphocytes.
   Google Scholar
• GARCIA-PERGANEDA A, POZO D, GUERRERO JM et al.:Signal transduction for melatonin in human lympho-cytes. Involvement of a pertussis toxin-sensitive G protein. J. Immunol. (1997) 159:3774–3781.
   Web of Science ®Google Scholar
• GUERRERO J-M, GARCIA-MAURINO S, GIL-HABA M et al.:Mechanisms of action on the human immune system: Membrane receptors versus nuclear receptors. In: Therapeutic potential of the Pineal Hormone Melatonin. Maestroni GJM, Conti A, Reiter RJ, (Eds.) Karger, Basel, Switzerland (1996):43–52.
   Google Scholar
• BARJAVEL MJ, MAMDOUH Z, RAGHBATE N et al.: Differ-ential expression of the melatonin receptor in human monocytes. J. lifirrlin70/. (1998) 160:1191–1197.
   Google Scholar
• RAFII-EL-IDRISSI M, CALVO JR, HARMOUCH A et al.: Specific binding of melatonin by purified cell nuclei from spleen and thymus of the rat. J. Nettraimmuna (1998) 86:190–197.
   PubMed Web of Science ®Google Scholar
• GARCIA-MAURINO S, GONZALES-HABA MG, CALVO JR etal.: Involvement of nuclear binding sites for melatonin in the regulation of IL-2 and IL-6 production in human blood mononuclear cells. J. Nettraimmunof (1998) 92:76–84.
   Google Scholar
• MAESTRONI GJM: The photoperiod transducermelatonin and the immune-hematopoietic system. J. Photoch. Photobiol. (1998) 43:186–192.
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of the MEL influence on immune and haemopoietic functions.
   Google Scholar
• WICHMANN M, ZELLWEGER R, DEMASO A et al.: Melatonin administration attenuates depressed immune functions after trauma-hemorrhage. J. Surg. Res. (1996) 63:256–262.
   PubMed Web of Science ®Google Scholar
• YELLON SM, TEASLEY LA, FAGOAGA OR et al.: Role ofphotoperiod and the pineal gland in T cell-dependent humoral immune reactivity in the Siberian hamster. J Pineal Res. (1999) 27:243–248.
   PubMed Web of Science ®Google Scholar
• KLIGER CA, GEHAD AE, HULET RM et al.: Effects ofphotoperiod and melatonin on lymphocyte activities in male broiler chickens. Pauli-. Sci. (2000) 79:18–25.
   PubMed Web of Science ®Google Scholar
• MOORE CB, SIOPES TD: Effects of lighting conditionsand melatonin supplementation of the cellular and humoral immune responses in Japanese quail Coturnix coturnix japonica. Gen. Comp. Endocrinol. (2000) 119:95–104.
   PubMed Web of Science ®Google Scholar
• PETROVSKY N, HARRISON L: Diurnal rhythmicity of human cytokine production. A dynamic disequilib-rium in T helper cell typel/T helper cell Type 2 balance. J. Immunol. (1996) 158:5163–5168.
   Google Scholar
• •Important observation of the immunological function of endogenous MEL in humans.
   Google Scholar
• FIORINA P, LATTUADA G, SILVESTRINI C et al.: Disrup- tion of nocturnal melatonin rhythm and immuno-logical involvement in ischaemic stroke patients. Scand. j Immunol. (1999) 50:228–231.
   PubMed Web of Science ®Google Scholar
• MOLINERO P, SOUTTO M, BENOT S et al.: Melatonin is responsible for the nocturnal increase observed in serum and thymus of thymosin al and thymulin concentrations: observations in rats and humans. J Neuroimmunol. (2000) 103:180–188.
   PubMed Web of Science ®Google Scholar
• LISSONI P, PITTALIS S, BARNI S et al.: Regulation of interleukin-2/interleukin-12 interactions by the pineal gland. Int. J. Thymology (1997) 5:443–447.
   Google Scholar
• GARCIA-MAURINO S, POZO D, CARILLO-VICO A et al.: Melatonin activates Thl lymphocytes by increasing IL-12 production. Life Sci. (1999) 65:2143–2150.
   PubMed Web of Science ®Google Scholar
• FJAERLY 0, LUND T, OSTERUD B: The effect of melatonin on cellular activation processes in human blood. J. Pineal Res. (1999) 26:50–55.
   PubMed Web of Science ®Google Scholar
• GARCIA- MAURINO S, POZO D, CALVO JR et al.: Correla-tion between nuclear melatonin receptor expression and enhanced cytokine production in human lympho-cytic and monocytic cell lines. J Pineal Res. (2000) 29:129–137.
   PubMed Web of Science ®Google Scholar
• •Convincing demonstration of the presence and function of MEL nuclear receptors in human immunocompetent cells.
   Google Scholar
• HOFBAUER LC, HEUFELDER AE: Endocrinology meets immunology: T lymphocytes as novel targets for melatonin. Eur. j Endocrinol. (1996) 1 3 4:424–425.
   Google Scholar
• MAESTRONI GJM, COVACCI V,CONTI A: Hematopoietic rescue via T-cell-dependent, endogenous GM-CSF by the pineal neurohormone melatonin in tumor bearing mice. Cancer Res. (1994) 54:2429–2432.
   PubMed Web of Science ®Google Scholar
• •Demonstration that MEL can rescue haemopoietic progeni-tors from the toxic action of cancer chemotherapeutic compounds without influencing their anticancer action.
   Google Scholar
• MAESTRONI GJM, CONTI A,LISSONI P: Colony-stimulating activity and hematopoietic rescue from cancer chemothereapy compounds are induced by melatonin via endogenous interleukin 4. Cancer Res. (1994) 54:4740–4743.
   PubMed Web of Science ®Google Scholar
• MAESTRONI GJM, ZAMMARETTI F, PEDRINIS E: Hemato-poietic effect of melatonin. Involvement of kl-opioid receptor on bone marrow macrophages and interleukin-1. J Pineal Res. (In Press).
   Google Scholar
• MAESTRONI G, HERTENS E, GALLI P et al.: Melatonin-induced T-helper cell hematopoietic cytokines resembling both interleukin-4 and dynorphin. J. Pineal Res. (1996) 21:131–139.
   PubMed Web of Science ®Google Scholar
• ANWAR MM, MAHFOUZ HA, SAYED AS: Potential protec-tive effects of melatonin on bone marrow of rats exposed to cytotoxic drugs. Comp. Biochem. Physiol. (1998) 119:493–591.
   Google Scholar
• RAPOZZI V, ZORZET S, COMELLI M et al.: Melatonin decreases bone marrow and lymphatic toxicity of adryamycin in mice bearing TLX5 lymphoma. Life Sci. (1998) 63:171–1713.
   Google Scholar
• LISSONI P, PAOLOROSSI F, ARDIZZOIA A et al.: A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state. J. Pineal Res. (1997) 23:15–19.
   PubMed Web of Science ®Google Scholar
• •Confirmation of the ability of MEL to rescue haemopoietic progenitors in cancer patients.
   Google Scholar
• GHIELMINI M, PAGANI 0, DE YONG Y et al.: Double blind randomized study on the myeloprotective effect of melatonin given in combination with carboplatin and etoposide in advanced lung cancer. Br. J Cancer (1998) 00:1058–1061.
   Google Scholar
• HASSAN MI, AHMED MI, KASSIM SK et al.: Cis-platinum-induced immunosuppression: ralationship with melatonin in human peripheral blood mononuclear cells. Clin. Biochem. (1999) 32:621–626.
   PubMed Web of Science ®Google Scholar
• •See reference 37.
   Google Scholar
• CURRIER NL, SUN LZ, MILLER SC: Exogenous melatonin: qualitative enhancement in vivo of cells mediating non-specific immunity. J. Nettroimmtmoi. (2000) 104:101–108.
   PubMed Web of Science ®Google Scholar
• YU Q, MILLER SC, OSMOND DG: Melatonin inhibits apoptosis during early B-cell development in mouse bone marrow. J. Pineal Res. (2000) 29:86–93.
   PubMed Web of Science ®Google Scholar
• •Evidence that also lymphoid progenitors may be influenced by MEL in the bone marrow.
   Google Scholar
• LOPEZ-GONZALES MA, GUERRERO JM, SANCHEZ B etal.: Melatonin restores and enhances the human type B tonsillar lymphocyte subset in recurrent acute tonsil-litis. Neurosci. Lett. (1998) 247:131–134.
   Google Scholar
• LOPEZ-GONZALES MA, GUERRERO JM, CEBALLO PEDRAJA JM et al.: Melatonin in palate tonsils with recurrent acute tonsillitis and tonsillar hyperthrophy. Acta Otorrinolaringol. Esp. (1998) 49:625–628.
   Google Scholar
• REITER RJ, MAESTRONI GJM: Melatonin in relation to the antioxidative defense and immune systems: possible impications for cell and organ transplanta-tion. J. Mal. Med. (1999) 77:36–39.
   Google Scholar
• TSAI TF, POPOVICI F, CERNESCU C et al.: West Nile encephalitis epidemic in southeastern Romania. Lancet (1998) 352(9130):767–771.
   PubMed Web of Science ®Google Scholar
• BEN-NATHAN D, MAESTRONI GJM,CONTI A: Protectiveeffect of melatonin in viral and bacterial infections. In: Frontiers in Hormone Research. Maestroni GJM, Conti A, Reiter JR (Eds.), Karger, Basel, (1997):72–81. A very significant biological effect of MEL in lethal viral and bacterial infections.
   Google Scholar
• BEN-NATHAN D, MAESTRONI GJM, CONTI A: Protective effect of melatonin in mice infected with encephalitis viruses. Arch. Viral. (1995)140:223–230.
   PubMed Web of Science ®Google Scholar
• •First evidence of the ability of MEL to protect against viral encephalitis.
   Google Scholar
• BONILLA E, VALEROFUENMAJOR N, PONS H et al.: Melatonin protects mice infected with Venezuelan equine encephalomyelitis virus. Cell Mol. Life Sci. (1997) 53:430–434.
   PubMed Web of Science ®Google Scholar
• BARRON RL: Pathophysiology of septic shock andimplications for therapy. Clin. Pharm. (1993) 12:829–845.
   PubMedGoogle Scholar
• BEASLEY D, ELDRIDGE M: Interleukin-1I3 and tumor necrosis factor-a synergistically induce NO synthase in rat vascular smooth muscle cells. Am. J. Physiol. (1994) 266:R1197–R1203.
   PubMed Web of Science ®Google Scholar
• CUNHA FQ, ASSREUY J, MOSS DW et al.: Differential induction of nitric oxide synthase in various organs of the mouse during endotoxaemia: role of TNF-a and IL-113. Immunology (1994) 81:211–215.
   PubMed Web of Science ®Google Scholar
• HIBBS JB Jr, TAINTOR RR, VAVRIN Z et al.: Synthesis of nitric oxide from a terminal guanidino atom of L-arginine: a molecular mechanism regulating cellular proliferation that targets intracellular iron. In: Nitric Oxide from L-arginine: a Bioregulatory System. Moncada sincerely, Higgs EA (Eds.), Excerpta Medica Elsevier, Amsterdam, (1991): 189–205.
   Google Scholar
• EVANS T, CARPENTER A, SILVA A et al.: Inhibition of nitric oxide synthase in experimental Gram-negative sepsis. J In! Dis. (1994) 169:343–349.
   PubMed Web of Science ®Google Scholar
• FLORQUIN S, AMRAOUI Z, DUBOIS C et al.: The protec-tive role of endogenously synthesized nitric oxide in staphylococcal enterotoxin B-induced shock in mice. J. Exp. Med. (1994) 180:1153–1158.
   PubMed Web of Science ®Google Scholar
• MAESTRONI GJM: Melatonin as a therapeutic agent in experimental endotoxic shock. J. Pineal Res. (1996) 20:84–89.
   PubMed Web of Science ®Google Scholar
• •Impressive protection exerted by MEL in a model of septic shock.
   Google Scholar
• GILAD E, WONG HR, ZINGARELLI B et al.: Melatonin inhibits expression of the inducible isoform of nitric oxide synthase in murine macrophages: role of inhibi-tion of NEkappB activation. FASEBJ (1998) 12:685–693.
   PubMed Web of Science ®Google Scholar
• SHIN S, HUR GH, KIM YB et al.: Dehydroiepiandros-terone and melatonin prevent Bacillus anthracis lethal toxin-induced INF production in macrophages. Cell. Biol. Toxicol. (2000) 16:1401–1405.
   Google Scholar
• HANSSON I, HOLMDAHL R, MATTSSON R: The pineal hormone melatonin exaggerates development of collagen-induced arthritis in mice. J Nettroimmuna (1992) 39:23–31.
   PubMed Web of Science ®Google Scholar
• CUTOLO M, VILLAGGIO B, CANDIDO F et al.: Melatonin influences interleukin-12 and nitric oxide production by primary cultures of rheumatoid synovial macrophages and THP-1 cells. Ann. NY Acad. Sci. (1999) 876:246–254.
   PubMed Web of Science ®Google Scholar
• •Evidence about a possible involvement of MEL in human autoimmunity.
   Google Scholar
• CONSTANTINESCU CS, HILLIARD B, VENTURA E et al.:Luzindole, a melatonin receptor antagonist, suppresses experimental autoimmune encephalo-myelitis. Pathobiology (1997) 65:190–194.
   PubMed Web of Science ®Google Scholar
• CLARK M, MAESTRONI GJM: Daylight length does notaffect experimental autoimmune encephalomyelitis (EAE), the animal model for multiple sclerosis (MS). Neuroimmunomodulation (In Press).
   Google Scholar
• WICHMANN MW, HAISKEN JM, AYALA A et al: Melatoninadministration following hemorrhagic shock decreases mortality from subsequent septic challenge. Surg. Res. (1996) 65:109–114.
   PubMed Web of Science ®Google Scholar
• BANKS RE, PATEL PM, SELBY PJ: Interleukin-12: a newplayer in cytokine therapy. Br. J. Cancer (1995) 71:655–659.
   PubMed Web of Science ®Google Scholar
• PARDOLL D: Cancer vaccines. Nature Med. (1998)4 (Suppl.):525–531.
   Google Scholar
• SEABRA WDV, BIGNOTTO M, PINTO LR et al.: Random-ized, double-blind clinical trial, controlled with placebo, of the toxicology of chronic melatonin treatment. J Pineal Res. (2000) 29:193–200.
   PubMed Web of Science ®Google Scholar
• SHAJI AV, KULKARNI SK, AGREWALA JN: Regulation of secretion of IL-4 and IgG1 isotype by melatonin-stimulated ovalbumin specific T cells. Clin. Exp. Immunol. (1998) 111:181–185.
   PubMed Web of Science ®Google Scholar
• ELENKOV IJ, CHROUSOS GP: Stress hormones, Thl /1h2 patterns, pro/anti-inflammatory cytokines and susceptibility to disease. Trends Endoc. Metabol. (1999) 1 0 :359–368.
   Google Scholar
• OLCESE J: Melatonin after four decades. An assessment of its potential. Kluwer Academic/Plenum, New York, USA (1999).
   Google Scholar
• CONTI A, CONCONI S, HERTENS E et al.: Evidence for melatonin synthesis in mouse and human bone marrow cells. J Pineal Res. (1999) 28:193–202.
   Web of Science ®Google Scholar
• •Demonstration that haemopoietic and immunocompetent cells do synthesise MEL in large amounts.
   Google Scholar
• TAN DX, MANCHESTER LC, REITER RJ etal.:Identification of higher elevated levels of melatonin in bone marrow: its origin and significance. Biochlin. Biophys. Acta (1999) 1472:206–214.
   Google Scholar